

## Product Datasheet

### MTX-23

Catalog No. **BP-02426** · CAS **2488296-74-6** · Form **free base** · Physical state **solid** · Color **Off-white to light yellow** · Version **1.0** · Revision **2026-09-11**


**FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.**

|                                                        |                                |
|--------------------------------------------------------|--------------------------------|
| Target<br><b>PROTACs; Androgen Receptor; Apoptosis</b> | Research area<br><b>Cancer</b> |
|--------------------------------------------------------|--------------------------------|

Molecular formula **C<sub>43</sub>H<sub>53</sub>F<sub>2</sub>N<sub>7</sub>O<sub>7</sub>S<sub>2</sub>**

Molecular weight **882.0500**

#### STRUCTURE



## DESCRIPTION

MTX-23 is a PROTAC degrader targeting androgen receptor splice variant 7 (AR-V7) and full-length androgen receptor (AR-FL), with DC50 values of 0.37  $\mu$ M and 2  $\mu$ M, respectively. MTX-23 binds to the DNA-binding domains of AR-V7 and AR-FL, recruits the VHL E3 ubiquitin ligase (E3 ubiquitin ligase) and induces their degradation. MTX-23 reduces the proliferation of prostate cancer cells, promotes their apoptosis (apoptosis), and also inhibits tumor growth in mouse models. MTX-23 can be used for the research of prostate cancer .

## BIOLOGICAL ACTIVITY

### In Vitro

MTX-23 degrades AR-V7 with a DC50 of 0.37  $\mu$ mol/L and AR-FL with a DC50 of 2  $\mu$ mol/L as measured by immunoblot analysis.

MTX-23 inhibits proliferation and increases apoptosis in androgen-responsive prostate cancer cells, with this antiproliferative effect dependent on the presence of AR-V7 and AR-FL.

MTX-23 inhibits proliferation in 12 human prostate cancer cell lines resistant to second-line antiandrogen therapies.

## SOLUBILITY

Soluble in DMSO : 100 mg/mL

## REFERENCES

[1].Lee GT, et al. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Mol Cancer Ther. 2021 Mar;20(3):490-499.

Lot CoA and SDS are separate documents.